FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3184254488> ?p ?o ?g. }

• W3184254488 endingPage "319" @default.
• W3184254488 startingPage "309" @default.
• W3184254488 abstract "Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear.We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. Patients received open-label pimavanserin for 12 weeks. Those who had a reduction from baseline of at least 30% in the score on the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions (SAPS-H+D, with higher scores indicating greater psychosis) and a Clinical Global Impression-Improvement (CGI-I) score of 1 (very much improved) or 2 (much improved) at weeks 8 and 12 were randomly assigned in a 1:1 ratio to continue receiving pimavanserin or to receive placebo for up to 26 weeks. The primary end point, assessed in a time-to-event analysis, was a relapse of psychosis as defined by any of the following: an increase of at least 30% in the SAPS-H+D score and a CGI-I score of 6 (much worse) or 7 (very much worse), hospitalization for dementia-related psychosis, stopping of the trial regimen or withdrawal from the trial for lack of efficacy, or use of antipsychotic agents for dementia-related psychosis.Of the 392 patients in the open-label phase, 41 were withdrawn for administrative reasons because the trial was stopped for efficacy; of the remaining 351 patients, 217 (61.8%) had a sustained response, of whom 105 were assigned to receive pimavanserin and 112 to receive placebo. A relapse occurred in 12 of 95 patients (13%) in the pimavanserin group and in 28 of 99 (28%) in the placebo group (hazard ratio, 0.35; 95% confidence interval, 0.17 to 0.73; P = 0.005). During the double-blind phase, adverse events occurred in 43 of 105 patients (41.0%) in the pimavanserin group and in 41 of 112 (36.6%) in the placebo group. Headache, constipation, urinary tract infection, and asymptomatic QT prolongation occurred with pimavanserin.In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation. Longer and larger trials are required to determine the effects of pimavanserin in dementia-related psychosis. (Funded by Acadia Pharmaceuticals; HARMONY ClinicalTrials.gov number, NCT03325556.)." @default.
• W3184254488 created "2021-08-02" @default.
• W3184254488 creator A5002451678 @default.
• W3184254488 creator A5004670943 @default.
• W3184254488 creator A5008831230 @default.
• W3184254488 creator A5022460546 @default.
• W3184254488 creator A5030515756 @default.
• W3184254488 creator A5032708452 @default.
• W3184254488 creator A5036718203 @default.
• W3184254488 creator A5037362183 @default.
• W3184254488 creator A5040419704 @default.
• W3184254488 creator A5049845140 @default.
• W3184254488 creator A5060487287 @default.
• W3184254488 creator A5087611468 @default.
• W3184254488 date "2021-07-22" @default.
• W3184254488 modified "2023-10-17" @default.
• W3184254488 title "Trial of Pimavanserin in Dementia-Related Psychosis" @default.
• W3184254488 cites W1847168837 @default.
• W3184254488 cites W1963580478 @default.
• W3184254488 cites W1968565337 @default.
• W3184254488 cites W1986856619 @default.
• W3184254488 cites W1990224774 @default.
• W3184254488 cites W1992139786 @default.
• W3184254488 cites W2012658469 @default.
• W3184254488 cites W2021809156 @default.
• W3184254488 cites W2035892177 @default.
• W3184254488 cites W2049349113 @default.
• W3184254488 cites W2083220625 @default.
• W3184254488 cites W2084561734 @default.
• W3184254488 cites W2102572922 @default.
• W3184254488 cites W2107881620 @default.
• W3184254488 cites W2109916969 @default.
• W3184254488 cites W2115017507 @default.
• W3184254488 cites W2128030851 @default.
• W3184254488 cites W2142274632 @default.
• W3184254488 cites W2157331971 @default.
• W3184254488 cites W2166609052 @default.
• W3184254488 cites W2344518133 @default.
• W3184254488 cites W2468352757 @default.
• W3184254488 cites W2786029268 @default.
• W3184254488 cites W2898955001 @default.
• W3184254488 cites W2902316203 @default.
• W3184254488 cites W2946407398 @default.
• W3184254488 cites W4232663087 @default.
• W3184254488 doi "https://doi.org/10.1056/nejmoa2034634" @default.
• W3184254488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34289275" @default.
• W3184254488 hasPublicationYear "2021" @default.
• W3184254488 type Work @default.
• W3184254488 sameAs 3184254488 @default.
• W3184254488 citedByCount "54" @default.
• W3184254488 countsByYear W31842544882021 @default.
• W3184254488 countsByYear W31842544882022 @default.
• W3184254488 countsByYear W31842544882023 @default.
• W3184254488 crossrefType "journal-article" @default.
• W3184254488 hasAuthorship W3184254488A5002451678 @default.
• W3184254488 hasAuthorship W3184254488A5004670943 @default.
• W3184254488 hasAuthorship W3184254488A5008831230 @default.
• W3184254488 hasAuthorship W3184254488A5022460546 @default.
• W3184254488 hasAuthorship W3184254488A5030515756 @default.
• W3184254488 hasAuthorship W3184254488A5032708452 @default.
• W3184254488 hasAuthorship W3184254488A5036718203 @default.
• W3184254488 hasAuthorship W3184254488A5037362183 @default.
• W3184254488 hasAuthorship W3184254488A5040419704 @default.
• W3184254488 hasAuthorship W3184254488A5049845140 @default.
• W3184254488 hasAuthorship W3184254488A5060487287 @default.
• W3184254488 hasAuthorship W3184254488A5087611468 @default.
• W3184254488 hasBestOaLocation W31842544881 @default.
• W3184254488 hasConcept C118552586 @default.
• W3184254488 hasConcept C126322002 @default.
• W3184254488 hasConcept C142724271 @default.
• W3184254488 hasConcept C204787440 @default.
• W3184254488 hasConcept C27081682 @default.
• W3184254488 hasConcept C2776000289 @default.
• W3184254488 hasConcept C2776412080 @default.
• W3184254488 hasConcept C2777952318 @default.
• W3184254488 hasConcept C2778548049 @default.
• W3184254488 hasConcept C2778715236 @default.
• W3184254488 hasConcept C2779134260 @default.
• W3184254488 hasConcept C2779483572 @default.
• W3184254488 hasConcept C2779727114 @default.
• W3184254488 hasConcept C2780494398 @default.
• W3184254488 hasConcept C71924100 @default.
• W3184254488 hasConceptScore W3184254488C118552586 @default.
• W3184254488 hasConceptScore W3184254488C126322002 @default.
• W3184254488 hasConceptScore W3184254488C142724271 @default.
• W3184254488 hasConceptScore W3184254488C204787440 @default.
• W3184254488 hasConceptScore W3184254488C27081682 @default.
• W3184254488 hasConceptScore W3184254488C2776000289 @default.
• W3184254488 hasConceptScore W3184254488C2776412080 @default.
• W3184254488 hasConceptScore W3184254488C2777952318 @default.
• W3184254488 hasConceptScore W3184254488C2778548049 @default.
• W3184254488 hasConceptScore W3184254488C2778715236 @default.
• W3184254488 hasConceptScore W3184254488C2779134260 @default.
• W3184254488 hasConceptScore W3184254488C2779483572 @default.
• W3184254488 hasConceptScore W3184254488C2779727114 @default.
• W3184254488 hasConceptScore W3184254488C2780494398 @default.
• W3184254488 hasConceptScore W3184254488C71924100 @default.
• W3184254488 hasFunder F4320315029 @default.

• next